Advertisement

Acta Neurochirurgica

, Volume 156, Issue 12, pp 2221–2230 | Cite as

An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly

  • Sauradeep Sarkar
  • Ari George Chacko
  • Geeta ChackoEmail author
Clinical Article - Brain Tumors

Abstract

Background

Despite the wide spectrum of adenoma behavior in patients with acromegaly, the ability of most pathological markers to predict clinical and radiological behavior remains controversial. The authors sought to comprehensively examine clinical and radiological correlates of growth hormone (GH)-secreting pituitary adenomas with regard to several commonly used immunocytochemical techniques in patients undergoing transsphenoidal surgery for acromegaly.

Method

We performed a retrospective review of histopathological findings in 101 surgically resected GH adenomas. Tumors were assessed radiologically for different patterns of extension. Each tumor specimen was subject to immunocytochemical analysis, including assessments of granulation patterns, MIB-1 labeling indices, prolactin cosecretion, p53 expression and mitotic activity. Endocrinological outcome was assessed in 93 patients, with remission defined by the 2010 consensus criteria.

Results

Most tumors were macroadenomas and almost half were invasive. When compared to densely granulated tumors, sparsely granulated adenomas were associated with a younger age at presentation, higher preoperative IGF-1 levels, elevated MIB-1 index and pure GH immunostaining, but did not differ significantly in terms of extrasellar invasion or outcome. Increased mitotic activity and p53 expression were also associated with higher proliferation indices and a younger age at presentation. Mixed GH/prolactin tumors demonstrated significantly higher remission rates, independent of variations in extrasellar growth. MIB-1 indices did not correlate with the preoperative GH/IGF-1 levels, adenoma size or Knosp grade.

Conclusion

The pathobiology of acromegaly is complex, and the clinicoradiological significance of subtyping on the basis of the markers employed in this study is debatable. Further investigation of newer molecular markers is warranted.

Keywords

Acromegaly Densely granulated adenomas Growth hormone MIB-1 index Sparsely granulated adenoma 

Notes

Conflicts of interest

None.

References

  1. 1.
    Albarel F, Castinetti F, Morange I, Conte‐Devolx B, Gaudart J, Dufour H, Brue T (2013) Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol (Oxf) 78:263–270CrossRefGoogle Scholar
  2. 2.
    Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, Sakoguchi T, Sugiyama K, Kurisu K, Yasufuku-Takano J (2010) Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae. Eur J Endocrinol 163:531–539PubMedCrossRefGoogle Scholar
  3. 3.
    Bando H, Sano T, Ohshima T, Zhang C, Yamasaki R, Matsumoto K, Saito S (1992) Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinol Jpn 39:355–363PubMedCrossRefGoogle Scholar
  4. 4.
    Barkan AL, Stred SE, Reno K, Markovs M, Hopwood NJ, Kelch RP, Beitins IZ (1989) Increased growth hormone pulse frequency in acromegaly. J Clin Endocrinol Metab 69:1225–1233PubMedCrossRefGoogle Scholar
  5. 5.
    Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015–2022PubMedCrossRefGoogle Scholar
  6. 6.
    Botelho CHA, Magalhães AV, Mello PA, Schmitt FC, Casulari LA (2006) Expression of p53, Ki-67 and c-erb B2 in growth hormone-and/or prolactin-secreting pituitary adenomas. Arq Neuropsiquiatr 64:60–66PubMedCrossRefGoogle Scholar
  7. 7.
    Chacko G, Chacko AG, Kovacs K, Scheithauer BW, Mani S, Muliyil J, Seshadri M (2010) The clinical significance of MIB-1 labeling index in pituitary adenomas. Pituitary 13:337–344PubMedCrossRefGoogle Scholar
  8. 8.
    Cottier JP, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469PubMedCrossRefGoogle Scholar
  9. 9.
    DeLellis R, Lloyd RV, Heitz P, Eng C (2004) World Health Organization classification of tumours: tumours of endocrine organs. IARC Press, LyonGoogle Scholar
  10. 10.
    Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797PubMedGoogle Scholar
  11. 11.
    Fougner SL, Casar‐Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76:96–102CrossRefGoogle Scholar
  12. 12.
    Fusco A, Zatelli M, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93:2746–2750PubMedCrossRefGoogle Scholar
  13. 13.
    Hartman ML, Veldhuis JD, Vance ML, Faria AC, Furlanetto W, Thorner MO (1990) Somatotropin pulse frequency and basal concentrations are increased in acromegaly and are reduced by successful therapy. J Clin Endocrinol Metab 70:1375–1384PubMedCrossRefGoogle Scholar
  14. 14.
    Hazer DB, Işık S, Berker D, Güler S, Gürlek A, Yücel T, Berker M (2013) Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria: Clinical article. J Neurosurg 119:1467–1477PubMedCrossRefGoogle Scholar
  15. 15.
    Hentschel SJ, McCutcheon IE, Moore W, Durity FA (2003) P53 and MIB-1 immunohistochemistry as predictors of the clinical behavior of nonfunctioning pituitary adenomas. Can J Neurol Sci 30:215–219PubMedGoogle Scholar
  16. 16.
    Hofstetter CP, Mannaa RH, Mubita L, Anand VK, Kennedy JW, Dehdashti AR, Schwartz TH (2010) Endoscopic endonasal transsphenoidal surgery for growth hormone-secreting pituitary adenomas. Neurosurg Focus 29:E6PubMedCrossRefGoogle Scholar
  17. 17.
    Jaffrain-Rea M, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Scucchi LF, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9:103–113PubMedCrossRefGoogle Scholar
  18. 18.
    Kawamoto H, Uozumi T, Kawamoto K, Arita K, Yano T, Hirohata T (1995) Analysis of the growth rate and cavernous sinus invasion of pituitary adenomas. Acta Neurochir (Wien) 136:37–43CrossRefGoogle Scholar
  19. 19.
    Kiseljak-Vassiliades K, Shafi S, Kerr JM, Phang TL, Kleinschmidt-DeMasters B, Wierman ME (2012) Clinical implications of growth hormone–secreting tumor subtypes. Endocrine 42:18–28PubMedCrossRefGoogle Scholar
  20. 20.
    Kontogeorgos G, Sambaziotis D, Piaditis G, Karameris A (1997) Apoptosis in human pituitary adenomas: a morphologic and in situ end-labeling study. Mod Pathol 10:921–926PubMedGoogle Scholar
  21. 21.
    Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115:261–262PubMedCrossRefGoogle Scholar
  22. 22.
    Kreutzer J, Vance M, Lopes M, Laws E (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86:4072–4077PubMedCrossRefGoogle Scholar
  23. 23.
    Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J (2008) The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93:2390–2401PubMedCrossRefGoogle Scholar
  24. 24.
    Lopes MBS (2010) Growth hormone-secreting adenomas: pathology and cell biology. Neurosurg Focus 29:E2PubMedCrossRefGoogle Scholar
  25. 25.
    Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M (2000) Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro-and macroadenomas. Am J Pathol 156:245–251PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Mantovani G, Lania A, Spada A (2010) GNAS imprinting and pituitary tumors. Mol Cell Endocrinol 326:15–18PubMedCrossRefGoogle Scholar
  27. 27.
    Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52:107–111PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Mayr B, Buslei R, Theodoropoulou M, Stalla GK, Buchfelder M, Schöfl C (2013) Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas. Eur J Endocrinol 169:391–400PubMedCrossRefGoogle Scholar
  29. 29.
    Mazal P, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N, Budka H (2001) Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol 20:163–171PubMedGoogle Scholar
  30. 30.
    McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB (2009) Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf) 71:226–233CrossRefGoogle Scholar
  31. 31.
    Mete O, Ezzat S, Asa SL (2012) Biomarkers of aggressive pituitary adenomas. J Mol Endocrinol 49:R69–R78PubMedCrossRefGoogle Scholar
  32. 32.
    Nehru GA, Pai R, Samuel P, Chacko AG, Chacko G (2012) Status of O 6-methylguanine-DNA methyltransferase [MGMT] gene promoter methylation among patients with glioblastomas from India. Neurol India 60:481–486PubMedCrossRefGoogle Scholar
  33. 33.
    Nyquist P, Laws ER Jr, Elliott E (1994) Novel features of tumors that secrete both growth hormone and prolactin in acromegaly. Neurosurgery 35:179–184PubMedCrossRefGoogle Scholar
  34. 34.
    Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Rahman MM, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19:82–91PubMedCrossRefGoogle Scholar
  35. 35.
    Osamura RY, Watanabe K (1987) Immunohistochemical colocalization of growth hormone (GH) and alpha subunit in human GH secreting pituitary adenomas. Virchows Arch A Pathol Anat Histopathol 411:323–30PubMedCrossRefGoogle Scholar
  36. 36.
    Pan LX, Chen ZP, Liu YS, Zhao JH (2005) Magnetic resonance imaging and biological markers in pituitary adenomas with invasion of the cavernous sinus space. J Neurooncol 74:71–76PubMedCrossRefGoogle Scholar
  37. 37.
    Sambaziotis D, Kapranos N, Kontogeorgos G (2003) Correlation of bcl-2 and bax with apoptosis in human pituitary adenomas. Pituitary 6:127–133PubMedCrossRefGoogle Scholar
  38. 38.
    Sano T, Ohshima T, Yamada S (1991) Expression of glycoprotein hormones and intracytoplasmic distribution of cytokeratin in growth hormone-producing pituitary adenomas. Pathol Res Pract 187:530–533PubMedCrossRefGoogle Scholar
  39. 39.
    Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapcer Ö, Young WF Jr, Meyer FB, Kuroki T (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59:341–353PubMedCrossRefGoogle Scholar
  40. 40.
    Shin SS, Tormenti MJ, Paluzzi A, Rothfus WE, Chang Y-F, Zainah H, Fernandez-Miranda JC, Snyderman CH, Challinor SM, Gardner PA (2012) Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary 16:435–444CrossRefGoogle Scholar
  41. 41.
    Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G (1990) Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 71:1421–1426PubMedCrossRefGoogle Scholar
  42. 42.
    Starke RM, Raper DM, Payne SC, Vance ML, Oldfield EH, Jane JA (2013) Endoscopic versus microsurgical transsphenoidal surgery for acromegaly: outcomes in a concurrent series of patients using modern criteria for remission. J Clin Endocrinol Metab 98:3190–3198PubMedCrossRefGoogle Scholar
  43. 43.
    Suliman M, Royds J, Cullen D, Timperley W, Powell T, Battersby R, Jones TH (2001) Mdm2 and the p53 pathway in human pituitary adenomas. Clin Endocrinol (Oxf) 54:317–325CrossRefGoogle Scholar
  44. 44.
    Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38:99–107PubMedCrossRefGoogle Scholar
  45. 45.
    Yamada S, Aiba T, Sano T, Kovacs K, Shishiba Y, Sawano S, Takada K (1993) Growth hormone-producing pituitary adenomas: correlations between clinical characteristics and morphology. Neurosurgery 33:20–27PubMedCrossRefGoogle Scholar
  46. 46.
    Yonezawa MDK, Tamaki MDN, Kokunai MDT (1997) Clinical features and growth fractions of pituitary adenomas. Surg Neurol 48:494–500PubMedCrossRefGoogle Scholar
  47. 47.
    Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications: Clinical article. J Neurosurg 114:336–344PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2014

Authors and Affiliations

  • Sauradeep Sarkar
    • 1
  • Ari George Chacko
    • 1
  • Geeta Chacko
    • 1
    • 2
    Email author
  1. 1.Section of Neurosurgery, Department of Neurological SciencesChristian Medical CollegeVelloreIndia
  2. 2.Section of Neuropathology, Department of Neurological SciencesChristian Medical CollegeVelloreIndia

Personalised recommendations